PT-141 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

PT-141 for Health & Longevity

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

An injected peptide acting on brain circuits for sexual motivation — the only approved drug of its kind. Its clearest effect is a modest rise in sexual desire, with a matching fall in distress, in women who have not reached menopause. Whether that change matters in daily life is contested. Nausea is common; most product sold outside pharmacies is unverified. (Full Review)

Protocol

Dose & route
1.75 mg subcutaneous
Single-dose autoinjector into abdomen or thigh, on an as-needed basis. Single dosing only; splitting is not supported.
Timing
≥ 45 min before activity
No circadian rationale; timing is dictated by anticipated activity. Earlier-evening dosing keeps nausea and the 2–4 hour pressure peak within waking hours.
Frequency ceiling
Maximum 8 doses per month
No more than one dose in 24 hours; use ends after 8 weeks without symptom improvement.
Time to effect
Desire & arousal effect
45 min – few hours
Per single dose, not after weeks of accumulation. The label states the duration of the effect after each dose is unknown.
Stopping point
8 weeks
The label directs stopping where there is no clear improvement after 8 weeks of appropriate dosing.
Fair personal trial
8–24 weeks
Roughly 8–20 doses; the phase 3 trials measured their endpoints at 24 weeks.

Benefits

Contraindications
  • Uncontrolled hypertension (persistently above roughly 140/90 mmHg, or any reading above 160/100 mmHg)
  • Known cardiovascular disease
  • Recent myocardial infarction or stroke, unstable angina, New York Heart Association Class III–IV heart failure, uncontrolled arrhythmia
  • Severe kidney impairment (eGFR below 30 mL/min/1.73 m²)
  • Severe liver impairment (Child-Pugh Class C)
  • Pregnancy or possible pregnancy, breastfeeding
  • Anyone under 18
  • Oral naltrexone for alcohol or opioid dependence
    •
Key Interactions
  • Oral drugs requiring threshold concentrations (antibiotics such as amoxicillin, doxycycline; indomethacin)
  • Over-the-counter decongestants (pseudoephedrine, phenylephrine, oral or high-dose nasal oxymetazoline)
  • Over-the-counter NSAIDs (ibuprofen, naproxen, aspirin at analgesic doses)
  • Antihypertensives and other blood-pressure-lowering agents (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics)
  • PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil)
  • Other melanocortin agonists (melanotan I, melanotan II, setmelanotide, afamelanotide)
  • Incretin-based agents (semaglutide, tirzepatide)
  • Blood-pressure-raising supplements (higher-dose caffeine, ephedra, yohimbine, synephrine, liquorice root)
  • Alcohol
    •

Risk & Side Effects

  • High: Nausea; discontinuation due to adverse effects; flushing; transient blood pressure increase and heart rate reduction
  • Medium: Focal hyperpigmentation; headache; injection site reactions; vomiting
  • Low: Impaired absorption of oral medications; hepatic injury; reproductive and developmental risk
  • Speculative: Melanocytic lesion and melanoma concern; unverified grey-market product

Monitoring

Marker Target Why
Blood pressure (home, seated average) < 120/80 mmHg Defines eligibility; each dose adds a transient rise
Resting heart rate 50–70 bpm Each dose lowers heart rate by up to 5 beats per minute
Apolipoprotein B (ApoB) < 80 mg/dL (< 60 mg/dL if other risk factors) Counts atherogenic particles; refines the cardiovascular-risk judgement the label requires
High-sensitivity C-reactive protein (hs-CRP) < 1.0 mg/L General inflammation marker feeding into cardiovascular risk stratification
Estimated glomerular filtration rate (eGFR) and creatinine eGFR > 90 mL/min/1.73 m² Exposure rises 1.5-fold at moderate and 2-fold at severe impairment
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ALT 10–26 U/L (women), 10–30 U/L (men) Baseline for the isolated hepatitis signal and for exposure-raising liver impairment
Thyroid-stimulating hormone (TSH) 0.5–2.0 mIU/L Thyroid underactivity is a common, reversible cause of low desire and fatigue
Prolactin < 15 ng/mL Raised prolactin directly suppresses sexual desire and sex hormones
Total and free testosterone with sex hormone-binding globulin (SHBG) Women: total 30–50 ng/dL; men: total 500–800 ng/dL; SHBG 30–60 nmol/L Androgen deficiency is a competing explanation for low desire and a competing treatment target
Follicle-stimulating hormone (FSH) and estradiol FSH < 10 IU/L with estradiol > 50 pg/mL (cycling women) Confirms premenopausal status, which defines the only population with efficacy data
Ferritin 50–100 ng/mL Iron deficiency without anaemia is a frequent cause of fatigue and low desire

Cadence: Home blood pressure on the day of the first dose and at 2, 4 and 8 hours after it; blood-pressure review at 4 weeks; full reassessment of symptoms at 8 weeks to decide on continuation; liver and kidney chemistry at 3 months; thereafter blood pressure quarterly with the full panel every 6–12 months, plus an annual skin review.

Qualitative Assessment

  • Frequency of spontaneous sexual thoughts or interest between doses, not only during the post-dose window
  • Distress about low desire, rated simply and consistently
  • Satisfaction with arousal during encounters following a dose
  • Nausea severity and duration by dose number
  • Flushing, headache, and warmth, with timing relative to injection
  • Any new or changing pigmented patch on the face, gums, breasts, or elsewhere, and any change in existing moles
  • Energy, sleep onset, and mood on dosing days versus non-dosing days
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.